- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | eXoZymes unveils new website and branding to reflect pharma focus | 4 | Investing.com | ||
| Di | With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation | 343 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 05.02. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.01. | eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run | 305 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.The... ► Artikel lesen | |
| 16.12.25 | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.12.25 | eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion | 351 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.11.25 | eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today | 359 | ACCESS Newswire | Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced... ► Artikel lesen | |
| 13.11.25 | eXoZymes appoints co-founder as CSO, adds new chief of staff | 5 | Investing.com | ||
| 13.11.25 | eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff | 349 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.11.25 | EXOZYMES INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.11.25 | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.11.25 | eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST | 338 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 30.10.25 | CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference | 340 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.10.25 | CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference | 340 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 23.10.25 | CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference | 292 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 03.10.25 | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09.25 | Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees | 359 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 12.08.25 | eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | 473 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered... ► Artikel lesen | |
| 08.08.25 | eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | 401 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.07.25 | eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | 518 | ACCESS Newswire | Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,185 | +0,43 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| EVOTEC | 5,960 | -0,53 % | Evotec-Aktie: War's das schon wieder oder geht's weiter hoch? | Nach dem kräftigen Kurssprung am Dienstag aufgrund einer Analysten-Empfehlung legt die Evotec-Aktie wieder leicht den Rückwärtsgang ein und notiert aktuell bei 6,25 €. War's das schon wieder? Oder bleibt... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,93 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 36,570 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Third Quarter 2025 Financial Results | Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction... ► Artikel lesen | |
| TYRA BIOSCIENCES | 27,850 | -7,14 % | William Blair startet Coverage für Tyra Biosciences mit "Outperform"-Rating | ||
| BIONTECH | 91,25 | -1,03 % | BioNTech-Konkurrent Moderna: Rückschlag - Aktie rauscht erneut nach unten | Wie jüngst bekannt wurde, weigert sich die US-Arzneimittelbehörde FDA, den Zulassungsantrag für den experimentellen Grippeimpfstoff mRNA-1010 überhaupt zu prüfen. Die Aktie von Moderna geriet am Dienstag... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,670 | -3,76 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 3,625 | -2,29 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ARCELLX | 69,04 | -1,15 % | Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns | ||
| VIKING THERAPEUTICS | 26,710 | +10,92 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 83,47 | +1,37 % | Kymera auf Guggenheim Biotech-Gipfel: CEO skizziert Potenzial oraler Medikamente | ||
| UPSTREAM BIO | 14,000 | -4,50 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 321,02 | -0,77 % | Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity | ||
| VALNEVA | 4,340 | +5,65 % | Valneva-HAMMER: Kurs schießt hoch - das steckt dahinter | ||
| BEAM THERAPEUTICS | 26,450 | +1,69 % | Beam Therapeutics Inc. - 8-K, Current Report |
EXOZYMES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 10,200 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.